PD-L1 Positivity Associated With Improved Efficacy of Pembrolizumab vs Ipilimumab

Share this content:
Programmed death-ligand 1 positivity is associated with improved efficacy with pembrolizumab in patients with advanced melanoma.
Programmed death-ligand 1 positivity is associated with improved efficacy with pembrolizumab in patients with advanced melanoma.

Programmed death-ligand 1 (PD-L1) positivity is associated with improved efficacy with pembrolizumab compared with ipilimumab in patients with advanced melanoma, a study presented at the American Academy for Cancer Research (AACR) Annual Meeting 2016 has shown.1

Both the anti-PD-1 monoclonal antibody pembrolizumab and the anti-CTLA-4 antibody ipilimumab have demonstrated efficacy in advanced melanoma, but the KEYNOTE-006 trial showed that pembrolizumab significantly improved progression-free survival, objective response rate, and overall survival compared with ipilimumab. Now, researchers have reported data on PD-L1 expression and efficacy from a second interim analysis of KEYNOTE-006.

For the study, researchers enrolled 834 ipilimumab-naïve patients with advanced melanoma. Of the 821 evaluable patients for PD-L1 expression, 82% were PD-L1 positive. Participants were randomly assigned 1:1:1 to receive pembrolizumab 10 mg/kg every 2 weeks, every 3 weeks, or ipilimumab for 4 cycles.

Results showed that pembrolizumab, given every 2 or 3 weeks, significantly improved progression-free survival (P < .00001), overall survival (P = .0005 for every 2 weeks and P = .0036 for every 3 weeks), and objective response rate (P = .00003 and P = .0001, respectively) compared with ipilimumab.

Further, researchers found that among patients with PD-L1-positive tumors, patients who received pembrolizumab had improved progression-free survival (HR, 0.52; 95% CI, 0.43 - 0.64), overall survival (HR, 0.56; 95% CI, 0.43 - 0.74), and objective response rate (P < .00001) to a greater extent than patients with PD-L1-negative tumors (progression-free survival: HR, 0.83; 95% CI, 0.55 - 1.26; overall survival: HR, 0.94; 95% CI, 0.56 - 1.6; objective response rate: P < .00001).

RELATED: Nivolumab Monotherapy Induces Durable, Long-term Survival in Advanced Melanoma

Investigators also observed a correlation between degree of PD-L1 positivity and improved efficacy with pembrolizumab compared with ipilimumab.

These findings ultimately suggest that pembrolizumab monotherapy is appropriate in patients irrespective of PD-L1 status.

Reference

  1. Carlino M, Ribas A, Gonzalez R, et al. KEYNOTE-006: PD-L1 expression and efficacy in patients (pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma. Oral presentation at: AACR Annual Meeting 2016; April 16-20, 2016; New Orleans, LA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs